US EditionNKGen activates new sites for Phase I/IIa study of Alzheimer’s cell therapy
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
NKGen activates new sites for Phase I/IIa study of Alzheimer’s cell therapy
NKGen Biotech has activated two new trial sites in Canada and Florida for the Phase I/IIa study of troculeucel to treat Alzheimer’s.The post NKGen activates new sites for Phase I/IIa study of Alzheimer’s cell therapy appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
